Volume :
5
Issue :
1
Abstract :
During the past decade, major improvements in the management of Acute Myocardial Infarction (AMI) patients have reduced AMI-related mortality by 50% in developed countries. Specifically, the introduction of intensive care units in the 1960s, improvement in pharmacologic reperfusion in the 1980s, and the widespread availability of percutaneous coronary intervention (PCI) in the 1990s have markedly reduced in-hospital mortality from AMI over the past 15 years.5 Furthermore, the near-universal acceptance and prompt application of antiplatelet agents, β-adrenergic blockers, angiotensin-converting enzyme (ACE) inhibitors, and statins after an AMI have contributed to the improvement in long-term survival among AMI patients. Still, these great strides cannot diminish the impact of MI. First, the number of at-risk patients (e.g., genetic predisposition, smoking, poor dietary habits, or physical inactivity) is enormous and continues to increase, especially the population of diabetics, elderly patients, and other individuals with metabolic syndrome [5, 6]. One such case with high risk and in need of Coronary Bypass Grafting (CABG) has been treated by Dr. Appa Rao’s Immunonutritive therapy and the result was beneficial to the patient. Patient was followed for a year and was found to be healthy.